Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 63

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 63
---
 date that the Company priced the private offering of the 2025 Notes.As of June 30, 2025, the 2025 Notes had a market price of $993 per $1,000 principal amount.Convertible Senior Notes Due 2024 Assumed from the Flexion AcquisitionPrior to the Flexion Acquisition, in May 2017, Flexion issued an aggregate of $201.3 million principal amount of 3.375% convertible senior notes due May 1, 2024 (the “Flexion 2024 Notes”), pursuant to an indenture between Flexion and Computershare Corporate Trust, N.A. (formerly Wells Fargo Bank, N.A.), as trustee (the “Flexion Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 19, 2021, between Flexion and the Flexion Trustee. Interest was payable semi-annually on May 1st and November 1st of each year. Upon the Flexion Acquisition, the principal was assumed and recorded at fair value by the Company. On January 7, 2022, following the expiration of the offer to purchase, the Company accepted the $192.6 million aggregate principal amount of Flexion 2024 Notes that were validly tendered (and not validly withdrawn). No Flexion 2024 Notes were converted in connection with the Notice. The remaining principal of $8.6 million was repaid at maturity on May 1, 2024. 

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 22

Interest ExpenseThe following table sets forth the total interest expense recognized in the periods presented (dollar amounts in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Contractual interest expense$3,823 $3,797 $7,685 $7,108 Amortization of debt issuance costs849 763 1,694 1,444 Amortization of debt discount23 23 45 47 Capitalized interest (Note 6)— (699)(149)(1,399)        Total$4,695 $3,884 $9,275 $7,200 Effective interest rate on total debt3.09 %2.99 %3.10 %2.98 %

NOTE 10—FIN